This document provides guidance on the planning of clinical studies concerning the treatment of post-traumatic stress disorder.
Keywords: Post-traumatic stress disorder (PTSD), anxiety disorder
Current effective version
Guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)
English (EN) (71.16 KB - PDF)
Document history
Overview of comments received on draft guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)
English (EN) (147.56 KB - PDF)
Draft guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)
English (EN) (61.08 KB - PDF)
Concept paper on the development of a guideline on the development of medicinal products for the treatment of post-traumatic stress disorder
English (EN) (65.09 KB - PDF)
Related content
- Clinical efficacy and safety: nervous system
- Directive 2001/83/EC
- Regulation (EC) No 1901/2006
- Clinical trials in small populations
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E7 Studies in support of special populations: geriatrics
- ICH E8 General considerations for clinical studies
- ICH E9 statistical principles for clinical trials
- ICH E10 Choice of control group in clinical trials
- ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline
- Investigation of drug interactions
- Pharmacokinetic studies in man